| 65.78 -1.36 (-2.03%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 85.28 |
1-year : | 90.97 |
| Resists | First : | 73.01 |
Second : | 77.88 |
| Pivot price | 68.46 |
|||
| Supports | First : | 65.12 |
Second : | 54.18 |
| MAs | MA(5) : | 67.16 |
MA(20) : | 69.96 |
| MA(100) : | 76.79 |
MA(250) : | 74.05 |
|
| MACD | MACD : | -2.6 |
Signal : | -2.5 |
| %K %D | K(14,3) : | 10.3 |
D(3) : | 14.2 |
| RSI | RSI(14): 31.9 |
|||
| 52-week | High : | 88.19 | Low : | 60.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SOLV ] has closed above bottom band by 16.1%. Bollinger Bands are 17.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 67.15 - 67.49 | 67.49 - 67.77 |
| Low: | 64.35 - 64.71 | 64.71 - 65 |
| Close: | 65.26 - 65.82 | 65.82 - 66.28 |
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
Fri, 20 Mar 2026
Solventum Corp. stock falls Friday, underperforms market - MarketWatch
Fri, 20 Mar 2026
SOLV SEC Filings - Solventum Corporation 10-K, 10-Q, 8-K Forms - Stock Titan
Fri, 20 Mar 2026
Solventum (SOLV) Q4 2025 adjusted diluted EPS reaches $1.57 on 3.5% organic sales growth - MSN
Thu, 19 Mar 2026
Here’s Why Adding Solventum Shares to Your Portfolio Makes Sense Right Now - Bitget
Thu, 19 Mar 2026
Here's Why You Should Hold Solventum Stock in Your Portfolio Now - Yahoo Finance UK
Thu, 19 Mar 2026
Wells Fargo & Company Upgrades Solventum (NYSE:SOLV) to Hold - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 173 (M) |
| Shares Float | 147 (M) |
| Held by Insiders | 14.9 (%) |
| Held by Institutions | 73.6 (%) |
| Shares Short | 3,550 (K) |
| Shares Short P.Month | 3,660 (K) |
| EPS | 8.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 29.1 |
| Profit Margin | 18.6 % |
| Operating Margin | 7 % |
| Return on Assets (ttm) | 2.9 % |
| Return on Equity (ttm) | 38.8 % |
| Qtrly Rev. Growth | -3.8 % |
| Gross Profit (p.s.) | 25.7 |
| Sales Per Share | 48.01 |
| EBITDA (p.s.) | 6.74 |
| Qtrly Earnings Growth | 100.8 % |
| Operating Cash Flow | 369 (M) |
| Levered Free Cash Flow | 633 (M) |
| PE Ratio | 7.4 |
| PEG Ratio | 0 |
| Price to Book value | 2.26 |
| Price to Sales | 1.37 |
| Price to Cash Flow | 30.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|